illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Taisho Pharmaceuticals
Company logo

Taisho Pharmaceuticals | Sustainability Performance

https://www.taisho.co.jp/en/

Researches, develops, and markets pharmaceutical and healthcare products, focusing on over-the-counter drugs, prescription medicines, and wellness solutions.

1912

Japan

5,001 - 10,000 employees

Pharmaceuticals

$1B - 10B in revenue

$100M - 500M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6918
Overall
#281
in Japan
#160
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

293 out of 311

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Rici Healthcare

Japan, Health Care, Hospital & Health Care


Company logo
Santen Pharmaceutical

Japan, Health Care, Pharmaceuticals


Company logo
Takeda Pharmaceutical

Japan, Health Care, Pharmaceuticals

Revenue

301.4B $, 2023▼11% YoY

R&D intensity

6.88% 2023

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Taisho Pharmaceutical Holdings Co Ltd, Japanese major OTC pharma (LipovitanD, Bridgemark), has faced sustained class actions over the contested 2023 USD 4.7 billion Uehara familyled takeprivate (USD 4.7 billion deal, Japan's largest historic management buyout) affecting Japanese institutional minority shareholders, plus periodic Japanese MHLW enforcement on inadequate disclosure.
Powered by illuminem

Revenue

301.4B $, FY2023▼11% YoY

EBITDA

39.4B $, FY2023▼9.1% YoY

Operating margin

8% Industry: -33▼47.5% YoY

Revenue & EBITDA

$301.4BFY2023 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

-9.4B 2023▼250.1% YoY

Capex

50.4B 2023▼71.4% YoY

Debt/equity ratio

0.0 Industry: 0▼NaN% YoY

R&D intensity

6.9%FY2023

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

2.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

282.0

▼ 2.5%

2021

268.2

▼ 3.4%

2022

301.4

▼ 1.9%

2023

297.6

2027

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Available

Recycling policy

Not available

Workplace health & safety policy

Available

13%
Independent Directors

1 out of 8 incl. management

Powered by illuminem

Overall score

71

Environment

99

Social

73

Governance

42

Exclusion screening

Adult content

Not available

Alcoholic

Available

Animal testing

Available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

image report
Available

Sustainability employees


Total sustainability employees

1


    Available in
    Scale package

    Access
  • Email

  • Email